AbCellera announced a new collaboration with Merck, through a subsidiary, to generate antibodies against an undisclosed disease target. Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function. The agreement grants Merck the option to develop antibody candidates identified through the collaboration for specified therapeutic applications.

Financial terms of the deal were not disclosed.